1. Home
  2. SCNX vs ELUT Comparison

SCNX vs ELUT Comparison

Compare SCNX & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scienture Holdings Inc.

SCNX

Scienture Holdings Inc.

HOLD

Current Price

$0.49

Market Cap

24.8M

Sector

Health Care

ML Signal

HOLD

Logo Elutia Inc.

ELUT

Elutia Inc.

HOLD

Current Price

$0.90

Market Cap

23.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCNX
ELUT
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.8M
23.3M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
SCNX
ELUT
Price
$0.49
$0.90
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$7.00
AVG Volume (30 Days)
1.5M
442.8K
Earning Date
11-13-2025
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$653,391.00
$21,746,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
207.88
24.08
52 Week Low
$0.46
$0.50
52 Week High
$4.40
$3.46

Technical Indicators

Market Signals
Indicator
SCNX
ELUT
Relative Strength Index (RSI) 42.25 61.23
Support Level $0.47 $0.74
Resistance Level $0.52 $1.08
Average True Range (ATR) 0.04 0.10
MACD 0.00 0.02
Stochastic Oscillator 21.49 61.82

Price Performance

Historical Comparison
SCNX
ELUT

About SCNX Scienture Holdings Inc.

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Share on Social Networks: